First RSV vaccine trial for infants offers significant results
Summary : Results from a phase 3 trial evaluating AstraZeneca and Sanofi’s jointly developed treatment nirsevimab – the first investigational long-acting antibody, designed to protect…
Summary : Results from a phase 3 trial evaluating AstraZeneca and Sanofi’s jointly developed treatment nirsevimab – the first investigational long-acting antibody, designed to protect…